Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in ...

St. Jude Children's Research Hospital scientists have discovered how tumors disable immune "gatekeeper" cells that alert the ...

A study shows aggressive lymphomas trigger inflammatory signals that reprogram stromal cells, disrupting lymph node structure ...

April 02, 2026) St. Jude Children's Research Hospital scientists have discovered how tumors disable immune "gatekeeper" cells that ...

Prize winner’s research reprograms tumor cells to trigger antitumor immunity   Cancer immunotherapies, such as checkpoint ...

Study also identifies potential path to making immunotherapy effective against the deadly, treatment-resistant cancer Katelyn ...

St. Jude Children's Research Hospital scientists have discovered how tumors disable immune "gatekeeper" cells that alert the rest of the immune system to the presence of cancer - and how restoring ...

iACT Stealth is designed to work in tandem with Pluristyx's FailSafe (R) technology. FailSafe's drug-inducible safety feature acts as a genetic "kill switch," allowing for the selective removal of any ...

iACT Stealth is designed to work in tandem with Pluristyx’s FailSafe® technology. FailSafe’s drug-inducible safety feature acts as a genetic “kill switch," allowing for the selective removal of any ...

Researchers have engineered a dual-targeting nanocarrier that safely sneaks potent chemotherapy past the blood-brain barrier. By homing in on a specific protein expressed by both the glioblastoma ...

A new metabolic mechanism describes how tumors disable “gatekeeper” cells to prevent immune response to cancer.